When the World Health Organization (WHO) updated its recommendations for the human papillomavirus (HPV) vaccine in late 2022, it stated that a single-dose schedule could provide a comparable efficacy and durability of cancer protection compared to a two-dose regimen.
Since sexually transmitted HPV causes more than 95% of cervical cancer, many countries sought independent clinical research to support the WHO's revised recommendation.
Is One HPV Vaccine Dose Enough Cancer Protection?
Some Immunosuppressed Do Not Have Anti-Spike Antibodies After COVID-19 Vaccination
IgG anti-spike antibodies undetectable in ~20 percent with immunosuppression who had received three or more COVID-19 vaccines
Hospital COVID-19 Burden Impacted NSTEMI Treatment, Outcome
Outcomes and treatment worse for patients hospitalized during weeks with a high hospital COVID-19 burden
No Change in Depression Seen in Children Across the Globe From 2004 to 2019
Findings based on 41 studies with data for children younger than 13 years old